Latest COVID-19 Vaccine Timetable Doesn’t Include Election Day

Operation Warp Speeds Moncef Slaoui, seen here at the White House in May, states medical trials of experimental COVID-19 vaccines will quickly expose if they work. Manufacture of the vaccines is selecting up speed.

Drew Angerer/Getty Images

toggle caption

hide caption

Drew Angerer/Getty Images

Operation Warp Speeds Moncef Slaoui, seen here at the White House in May, states scientific trials of speculative COVID-19 vaccines will soon expose if they work. Manufacture of the vaccines is selecting up speed.

Drew Angerer/Getty Images

Moncef Slaoui, chief consultant to the Trump administrations Operation Warp Speed program, has actually designed the timetable for when he believes a COVID-19 vaccine might be ready, at least for some people residing in the United States.

The other four vaccine efforts Operation Warp Speed is supporting– AstraZeneca/University of Oxford, Johnson & & Johnson, Novavax, and Sanofi/GlaxoSmithKline– are weeks to months behind Moderna and Pfizer.

And Election Day doesnt figure into his forecast.

Vaccines utilizing this technique can be developed quickly, but to date the Food and Drug Administration has not certified a vaccine based on messenger RNA.

He made his predictions during an online seminar arranged by Johns Hopkins University and the University of Washington on Tuesday.

He said the business are making development.

Initial testing of these vaccines was favorable, and large-scale safety and efficacy trials including 10s of thousands of volunteers are underway.

” We are in the process of stockpiling vaccine doses in the single-digit million doses in the month of October, November, and after that in the 10s of countless dosages in November,” Slaoui said.

Slaoui said making tens of thousands of dosages in one thing: “Producing tens or millions or hundreds of countless dosages of vaccine is a really different story.”

Slaoui described the progress made by 6 companies supported by Operation Warp Speed.

The 2 farthest along are Moderna and Pfizer. Both of their vaccines are based upon messenger RNA technology, an innovation that injects hereditary directions from the coronavirus into individuals, and coaxes the receivers cells into producing proteins that resemble an infection but arent infections.

Slaoui said it shouldnt be long before the business know if the vaccines are working. “Nobody can truly state when,” he stated, “however the expectation would be that this would occur in between the month of November and December.”

However Saloui said showing that a vaccine works and getting it approved by the FDA is just half the story. The other, more hard half is “to scale up and to industrially produce these vaccines.”

By January he expects there will be 30 million dosages of each one of messenger RNA vaccines. That should suffice to inoculate a great portion of people most at danger of contracting COVID-19 by early next year, he stated, “and start to substantially impact this pandemic.”